Hard-to-treat myasthenia gravis (MG) is, quite frankly, a thorn in the side of anyone dealing with this condition. Imagine this: a disease affecting 150 to 200 people per million globally, yet many are left undiagnosed. In the U.S., about 37 out of every 100,000 individuals have MG, and the numbers are climbing. Great, right? That’s just what we need—more people to join this frustrating club.
MG doesn’t discriminate. It affects all races and ethnicities, but some variations are curious. Like how African Americans often develop it younger and deal with MuSK antibodies, which sounds fancy but means tougher treatment. Go figure. The majority of cases are generalized myasthenia gravis (gMG), and they’re increasingly showing up in older adults. The average age of diagnosis is creeping up, especially among men over 65. So, if you thought MG was just a young person’s game, think again.
MG doesn’t discriminate; it hits all ages and races, with surprising trends among African Americans and older adults.
The real kicker? Hard-to-treat MG refers to cases that don’t respond well to the usual treatments. You know, the corticosteroids and immunosuppressants that should help but often don’t. It’s like ordering a pizza and getting a salad instead. Approximately 3.2 new MG cases diagnosed per 100,000 people annually adds to the complexity of managing this condition.
Subtypes like MuSK-antibody positive MG and late-onset MG? They’re the real divas of the MG world, throwing tantrums with their atypical disease courses and severe symptoms.
But wait, there’s hope. Recent advances in treatment are shaking things up. New immunotherapies, complement inhibitors, and FcRn antagonists are on the scene. They’re offering options for those who thought they were out of luck.
Thymectomy, the surgical removal of the thymus, is still a go-to for some. Emerging biologics are also making waves in clinical trials.
